| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 167 | 2023 | 432 | 34.970 |
Why?
|
| Rhinitis | 145 | 2023 | 383 | 31.500 |
Why?
|
| Endoscopy | 118 | 2022 | 464 | 18.170 |
Why?
|
| Nasal Polyps | 75 | 2023 | 184 | 15.730 |
Why?
|
| Paranasal Sinuses | 63 | 2023 | 165 | 13.530 |
Why?
|
| Olfaction Disorders | 36 | 2022 | 100 | 12.770 |
Why?
|
| Chronic Disease | 142 | 2023 | 1329 | 7.680 |
Why?
|
| Skull Base | 27 | 2022 | 72 | 7.100 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 27 | 2019 | 41 | 6.310 |
Why?
|
| Rhinitis, Allergic, Perennial | 19 | 2021 | 43 | 5.940 |
Why?
|
| Quality of Life | 60 | 2023 | 1515 | 5.840 |
Why?
|
| Smell | 35 | 2022 | 131 | 5.630 |
Why?
|
| Humans | 329 | 2023 | 68549 | 3.950 |
Why?
|
| Nasal Mucosa | 23 | 2020 | 68 | 3.850 |
Why?
|
| Nasal Cavity | 19 | 2021 | 62 | 3.740 |
Why?
|
| Mycoses | 15 | 2020 | 60 | 3.630 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 19 | 2019 | 62 | 3.570 |
Why?
|
| Rhinitis, Allergic | 10 | 2023 | 22 | 3.480 |
Why?
|
| Nasal Obstruction | 10 | 2022 | 34 | 3.470 |
Why?
|
| Paranasal Sinus Diseases | 13 | 2022 | 30 | 3.330 |
Why?
|
| Postoperative Complications | 23 | 2022 | 1615 | 3.080 |
Why?
|
| Middle Aged | 144 | 2021 | 21119 | 3.070 |
Why?
|
| Adult | 137 | 2022 | 21379 | 2.860 |
Why?
|
| Male | 168 | 2023 | 37283 | 2.840 |
Why?
|
| Female | 163 | 2023 | 38021 | 2.780 |
Why?
|
| Tomography, X-Ray Computed | 42 | 2023 | 2324 | 2.710 |
Why?
|
| Aged | 95 | 2022 | 14842 | 2.390 |
Why?
|
| Cerebrospinal Fluid Leak | 11 | 2020 | 32 | 2.360 |
Why?
|
| Respiratory Mucosa | 11 | 2018 | 52 | 2.320 |
Why?
|
| Pituitary Neoplasms | 6 | 2020 | 52 | 2.190 |
Why?
|
| Encephalocele | 12 | 2020 | 30 | 2.150 |
Why?
|
| Orbital Diseases | 3 | 2020 | 21 | 2.090 |
Why?
|
| Reoperation | 10 | 2020 | 467 | 2.010 |
Why?
|
| Treatment Outcome | 60 | 2022 | 7028 | 2.010 |
Why?
|
| Cystic Fibrosis | 10 | 2022 | 283 | 2.010 |
Why?
|
| Nasal Surgical Procedures | 7 | 2020 | 21 | 1.980 |
Why?
|
| Rhinitis, Allergic, Seasonal | 4 | 2021 | 22 | 1.950 |
Why?
|
| Taste | 5 | 2018 | 49 | 1.920 |
Why?
|
| Depression | 7 | 2018 | 942 | 1.900 |
Why?
|
| Nasal Septum | 8 | 2020 | 16 | 1.880 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2017 | 127 | 1.870 |
Why?
|
| Prospective Studies | 42 | 2022 | 3703 | 1.870 |
Why?
|
| Surveys and Questionnaires | 26 | 2021 | 2798 | 1.860 |
Why?
|
| Asthma, Aspirin-Induced | 3 | 2022 | 4 | 1.760 |
Why?
|
| Dendritic Cells | 7 | 2017 | 201 | 1.750 |
Why?
|
| Retrospective Studies | 59 | 2021 | 7268 | 1.720 |
Why?
|
| Adrenal Cortex Hormones | 11 | 2018 | 186 | 1.690 |
Why?
|
| Asthma | 8 | 2022 | 345 | 1.650 |
Why?
|
| Immunoglobulin E | 7 | 2018 | 91 | 1.590 |
Why?
|
| Paranasal Sinus Neoplasms | 9 | 2021 | 23 | 1.550 |
Why?
|
| Ethmoid Bone | 4 | 2019 | 18 | 1.510 |
Why?
|
| Desensitization, Immunologic | 5 | 2020 | 25 | 1.510 |
Why?
|
| Adolescent | 45 | 2020 | 8904 | 1.440 |
Why?
|
| Epithelial Cells | 9 | 2022 | 431 | 1.440 |
Why?
|
| Rhinoplasty | 6 | 2020 | 27 | 1.370 |
Why?
|
| Antigens, Fungal | 5 | 2015 | 19 | 1.350 |
Why?
|
| Young Adult | 34 | 2021 | 5710 | 1.320 |
Why?
|
| Therapeutic Irrigation | 8 | 2012 | 63 | 1.310 |
Why?
|
| Pneumocephalus | 4 | 2019 | 12 | 1.260 |
Why?
|
| Vitamin D Deficiency | 5 | 2017 | 292 | 1.240 |
Why?
|
| Cytokines | 9 | 2022 | 866 | 1.220 |
Why?
|
| Child | 36 | 2020 | 6401 | 1.210 |
Why?
|
| Maxillary Sinusitis | 4 | 2019 | 7 | 1.210 |
Why?
|
| Follow-Up Studies | 30 | 2020 | 3256 | 1.200 |
Why?
|
| Aged, 80 and over | 26 | 2020 | 4843 | 1.180 |
Why?
|
| Surgical Flaps | 5 | 2011 | 120 | 1.150 |
Why?
|
| Allergens | 7 | 2023 | 54 | 1.140 |
Why?
|
| Mucocele | 6 | 2011 | 20 | 1.120 |
Why?
|
| Odorants | 5 | 2022 | 52 | 1.090 |
Why?
|
| Turbinates | 8 | 2022 | 12 | 1.070 |
Why?
|
| Mucus | 6 | 2022 | 33 | 1.050 |
Why?
|
| Case-Control Studies | 16 | 2021 | 1549 | 1.040 |
Why?
|
| Nose Neoplasms | 5 | 2017 | 25 | 1.040 |
Why?
|
| Hypersensitivity | 5 | 2023 | 52 | 1.040 |
Why?
|
| Olfactory Mucosa | 3 | 2019 | 11 | 1.030 |
Why?
|
| Smoke | 2 | 2017 | 46 | 1.030 |
Why?
|
| Intracranial Hypertension | 8 | 2019 | 53 | 1.000 |
Why?
|
| Respiratory Tract Diseases | 3 | 2020 | 43 | 0.990 |
Why?
|
| Eustachian Tube | 3 | 2022 | 31 | 0.990 |
Why?
|
| Meningitis | 4 | 2020 | 23 | 0.980 |
Why?
|
| Staphylococcus aureus | 4 | 2014 | 175 | 0.980 |
Why?
|
| Tobacco | 2 | 2017 | 161 | 0.980 |
Why?
|
| Child, Preschool | 18 | 2020 | 3187 | 0.970 |
Why?
|
| Drug Delivery Systems | 3 | 2013 | 236 | 0.960 |
Why?
|
| Maxilla | 3 | 2011 | 63 | 0.960 |
Why?
|
| Nose Deformities, Acquired | 2 | 2021 | 6 | 0.960 |
Why?
|
| Ear Diseases | 2 | 2022 | 37 | 0.940 |
Why?
|
| Nasal Lavage | 3 | 2017 | 6 | 0.940 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2019 | 114 | 0.940 |
Why?
|
| Empty Sella Syndrome | 6 | 2011 | 10 | 0.940 |
Why?
|
| Maxillary Sinus | 3 | 2019 | 12 | 0.940 |
Why?
|
| Natural Orifice Endoscopic Surgery | 4 | 2020 | 24 | 0.910 |
Why?
|
| Cholecalciferol | 6 | 2017 | 143 | 0.910 |
Why?
|
| Mucociliary Clearance | 8 | 2012 | 21 | 0.890 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 4 | 2007 | 16 | 0.890 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 4 | 2007 | 15 | 0.880 |
Why?
|
| Age Factors | 8 | 2020 | 1860 | 0.870 |
Why?
|
| Intraoperative Complications | 4 | 2020 | 129 | 0.860 |
Why?
|
| Olfactory Bulb | 3 | 2019 | 14 | 0.860 |
Why?
|
| Neurosurgical Procedures | 6 | 2022 | 98 | 0.860 |
Why?
|
| Fungi | 3 | 2012 | 27 | 0.840 |
Why?
|
| Sphenoid Sinus | 5 | 2015 | 10 | 0.830 |
Why?
|
| Anti-Bacterial Agents | 12 | 2022 | 1026 | 0.830 |
Why?
|
| Cranial Fossa, Anterior | 3 | 2020 | 8 | 0.820 |
Why?
|
| Cross-Sectional Studies | 14 | 2022 | 2265 | 0.820 |
Why?
|
| Prognosis | 14 | 2021 | 2093 | 0.820 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 3 | 2017 | 10 | 0.810 |
Why?
|
| Superoxide Dismutase | 2 | 2015 | 149 | 0.810 |
Why?
|
| Frontal Sinus | 6 | 2008 | 14 | 0.810 |
Why?
|
| Headache | 1 | 2022 | 68 | 0.810 |
Why?
|
| Comorbidity | 13 | 2022 | 1425 | 0.780 |
Why?
|
| Cadaver | 11 | 2018 | 136 | 0.770 |
Why?
|
| Severity of Illness Index | 16 | 2021 | 1851 | 0.770 |
Why?
|
| Nose Diseases | 2 | 2016 | 8 | 0.760 |
Why?
|
| Administration, Intranasal | 5 | 2021 | 88 | 0.760 |
Why?
|
| Length of Stay | 3 | 2019 | 780 | 0.750 |
Why?
|
| Craniopharyngioma | 2 | 2020 | 7 | 0.750 |
Why?
|
| Otolaryngologists | 1 | 2020 | 5 | 0.740 |
Why?
|
| Loneliness | 1 | 2020 | 20 | 0.740 |
Why?
|
| Population Groups | 1 | 2020 | 16 | 0.740 |
Why?
|
| Bacterial Infections | 2 | 2020 | 163 | 0.730 |
Why?
|
| Immunotherapy | 3 | 2013 | 215 | 0.730 |
Why?
|
| Risk Assessment | 12 | 2020 | 2004 | 0.730 |
Why?
|
| Intracranial Pressure | 3 | 2012 | 58 | 0.730 |
Why?
|
| Incidence | 12 | 2020 | 1582 | 0.720 |
Why?
|
| Ethmoid Sinus | 4 | 2015 | 15 | 0.720 |
Why?
|
| Brain Diseases | 2 | 2019 | 78 | 0.720 |
Why?
|
| Risk Factors | 14 | 2020 | 5720 | 0.710 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 24 | 0.710 |
Why?
|
| Heart Diseases | 1 | 2022 | 276 | 0.700 |
Why?
|
| Cohort Studies | 15 | 2020 | 2356 | 0.690 |
Why?
|
| Calcitriol | 3 | 2022 | 106 | 0.690 |
Why?
|
| Temporal Bone | 2 | 2010 | 53 | 0.690 |
Why?
|
| Racism | 1 | 2020 | 59 | 0.690 |
Why?
|
| Acute Disease | 7 | 2020 | 658 | 0.690 |
Why?
|
| Prevalence | 9 | 2020 | 1609 | 0.690 |
Why?
|
| Aspergillus fumigatus | 4 | 2018 | 27 | 0.680 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 40 | 0.680 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.680 |
Why?
|
| Fatigue | 3 | 2019 | 132 | 0.670 |
Why?
|
| Glucocorticoids | 6 | 2020 | 222 | 0.670 |
Why?
|
| Orbit | 3 | 2015 | 30 | 0.660 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2015 | 21 | 0.650 |
Why?
|
| Bone Diseases, Infectious | 2 | 2009 | 2 | 0.640 |
Why?
|
| Adenoma | 2 | 2020 | 132 | 0.640 |
Why?
|
| Skull Base Neoplasms | 3 | 2019 | 13 | 0.630 |
Why?
|
| Mouth | 1 | 2018 | 64 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 772 | 0.620 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 133 | 0.620 |
Why?
|
| Phenotype | 6 | 2022 | 946 | 0.610 |
Why?
|
| Meningocele | 2 | 2011 | 12 | 0.610 |
Why?
|
| Transferrin | 2 | 2011 | 94 | 0.600 |
Why?
|
| Alternaria | 2 | 2015 | 4 | 0.600 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2021 | 2222 | 0.600 |
Why?
|
| Aspergillosis | 2 | 2011 | 20 | 0.590 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 37 | 0.590 |
Why?
|
| Frontal Sinusitis | 3 | 2010 | 5 | 0.590 |
Why?
|
| Seizures | 1 | 2019 | 279 | 0.580 |
Why?
|
| Anxiety | 2 | 2018 | 422 | 0.580 |
Why?
|
| Dilatation | 2 | 2018 | 58 | 0.570 |
Why?
|
| Feeding and Eating Disorders | 1 | 2018 | 106 | 0.570 |
Why?
|
| Antifungal Agents | 2 | 2014 | 108 | 0.570 |
Why?
|
| Hair | 2 | 2014 | 46 | 0.570 |
Why?
|
| Interleukin-8 | 3 | 2015 | 71 | 0.570 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1140 | 0.570 |
Why?
|
| United States | 20 | 2022 | 7338 | 0.560 |
Why?
|
| Health Care Costs | 1 | 2019 | 346 | 0.560 |
Why?
|
| SEER Program | 2 | 2021 | 150 | 0.550 |
Why?
|
| Pulmonary Surfactants | 2 | 2007 | 41 | 0.550 |
Why?
|
| Vitamin D | 4 | 2022 | 516 | 0.550 |
Why?
|
| Bandages | 2 | 2013 | 33 | 0.550 |
Why?
|
| Laryngoscopy | 1 | 2016 | 61 | 0.550 |
Why?
|
| Cilia | 5 | 2012 | 94 | 0.540 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 4 | 0.540 |
Why?
|
| Otologic Surgical Procedures | 1 | 2016 | 23 | 0.540 |
Why?
|
| Antigens | 2 | 2017 | 90 | 0.540 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 109 | 0.540 |
Why?
|
| Risk | 4 | 2020 | 563 | 0.540 |
Why?
|
| Mucous Membrane | 4 | 2011 | 66 | 0.540 |
Why?
|
| Hamartoma | 1 | 2016 | 24 | 0.540 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 35 | 0.530 |
Why?
|
| Fluorescein | 3 | 2015 | 15 | 0.530 |
Why?
|
| Depressive Disorder | 2 | 2018 | 621 | 0.530 |
Why?
|
| Evidence-Based Medicine | 7 | 2019 | 438 | 0.530 |
Why?
|
| Administration, Sublingual | 6 | 2013 | 15 | 0.520 |
Why?
|
| Eosinophilia | 2 | 2014 | 47 | 0.520 |
Why?
|
| Osteotomy | 1 | 2015 | 46 | 0.520 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 373 | 0.510 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 156 | 0.510 |
Why?
|
| Otolaryngology | 3 | 2014 | 38 | 0.500 |
Why?
|
| Cluster Analysis | 4 | 2022 | 219 | 0.490 |
Why?
|
| Steroids | 7 | 2020 | 84 | 0.490 |
Why?
|
| Gene Expression | 2 | 2007 | 770 | 0.490 |
Why?
|
| Adenoids | 5 | 2012 | 15 | 0.490 |
Why?
|
| Inflammation | 6 | 2019 | 1030 | 0.490 |
Why?
|
| Sodium Chloride | 3 | 2014 | 136 | 0.480 |
Why?
|
| Evidence-Based Practice | 2 | 2013 | 146 | 0.480 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2012 | 133 | 0.480 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.470 |
Why?
|
| Complex Mixtures | 2 | 2014 | 14 | 0.470 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 191 | 0.470 |
Why?
|
| Leukotriene Antagonists | 1 | 2013 | 13 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2010 | 444 | 0.460 |
Why?
|
| Nicotine | 2 | 2014 | 350 | 0.460 |
Why?
|
| Silver | 1 | 2014 | 49 | 0.460 |
Why?
|
| Epistaxis | 2 | 2014 | 6 | 0.460 |
Why?
|
| Immunohistochemistry | 8 | 2014 | 1174 | 0.450 |
Why?
|
| Th2 Cells | 2 | 2011 | 48 | 0.450 |
Why?
|
| Intracranial Hypotension | 1 | 2012 | 4 | 0.440 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.430 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2009 | 52 | 0.430 |
Why?
|
| Pollen | 1 | 2012 | 6 | 0.430 |
Why?
|
| Dust | 1 | 2012 | 9 | 0.430 |
Why?
|
| Demography | 3 | 2022 | 279 | 0.420 |
Why?
|
| Pilot Projects | 7 | 2022 | 1341 | 0.410 |
Why?
|
| Cognition Disorders | 1 | 2015 | 342 | 0.410 |
Why?
|
| Equipment Contamination | 1 | 2012 | 38 | 0.410 |
Why?
|
| Craniotomy | 3 | 2009 | 33 | 0.410 |
Why?
|
| Catheterization | 1 | 2012 | 209 | 0.400 |
Why?
|
| Postoperative Hemorrhage | 3 | 2014 | 69 | 0.400 |
Why?
|
| Nasal Decongestants | 2 | 2018 | 7 | 0.400 |
Why?
|
| Nose | 5 | 2020 | 36 | 0.390 |
Why?
|
| Fistula | 1 | 2011 | 29 | 0.390 |
Why?
|
| Th1 Cells | 2 | 2011 | 101 | 0.390 |
Why?
|
| Sleep Wake Disorders | 3 | 2018 | 94 | 0.390 |
Why?
|
| Fluorescent Dyes | 2 | 2015 | 191 | 0.390 |
Why?
|
| Pterygopalatine Fossa | 1 | 2011 | 2 | 0.390 |
Why?
|
| Cells, Cultured | 5 | 2017 | 2673 | 0.390 |
Why?
|
| Pseudotumor Cerebri | 1 | 2011 | 43 | 0.380 |
Why?
|
| Dexamethasone | 1 | 2011 | 150 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 561 | 0.380 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 499 | 0.370 |
Why?
|
| Health Status Indicators | 3 | 2018 | 117 | 0.370 |
Why?
|
| Eosinophils | 5 | 2022 | 60 | 0.370 |
Why?
|
| Microbiota | 3 | 2020 | 79 | 0.370 |
Why?
|
| Sleep | 4 | 2020 | 263 | 0.370 |
Why?
|
| Biological Products | 3 | 2020 | 78 | 0.370 |
Why?
|
| Logistic Models | 4 | 2020 | 1419 | 0.360 |
Why?
|
| Oculomotor Muscles | 1 | 2010 | 54 | 0.350 |
Why?
|
| Obesity | 2 | 2015 | 1074 | 0.350 |
Why?
|
| Salvage Therapy | 1 | 2010 | 82 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2014 | 929 | 0.350 |
Why?
|
| Nasal Sprays | 3 | 2021 | 11 | 0.350 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2009 | 7 | 0.350 |
Why?
|
| Nerve Growth Factor | 1 | 2009 | 54 | 0.350 |
Why?
|
| Maxillary Diseases | 1 | 2009 | 13 | 0.350 |
Why?
|
| Databases, Factual | 4 | 2019 | 621 | 0.340 |
Why?
|
| Biomarkers | 8 | 2022 | 1593 | 0.340 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 955 | 0.330 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2022 | 51 | 0.330 |
Why?
|
| Bacteria | 2 | 2020 | 193 | 0.330 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 160 | 0.330 |
Why?
|
| Skull | 2 | 2006 | 63 | 0.330 |
Why?
|
| Anti-Allergic Agents | 1 | 2009 | 27 | 0.330 |
Why?
|
| Complement System Proteins | 1 | 2010 | 135 | 0.320 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 117 | 0.320 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 2077 | 0.320 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 124 | 0.320 |
Why?
|
| Sex Distribution | 4 | 2015 | 272 | 0.310 |
Why?
|
| Administration, Topical | 6 | 2013 | 111 | 0.310 |
Why?
|
| Hemostatics | 1 | 2008 | 47 | 0.310 |
Why?
|
| Biopsy | 5 | 2013 | 539 | 0.310 |
Why?
|
| Antibodies | 3 | 2015 | 241 | 0.310 |
Why?
|
| Thrombin | 1 | 2008 | 117 | 0.310 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 79 | 0.310 |
Why?
|
| Infant | 6 | 2020 | 2891 | 0.300 |
Why?
|
| Sphenoid Sinusitis | 2 | 2010 | 4 | 0.300 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2007 | 8 | 0.300 |
Why?
|
| Sex Factors | 5 | 2018 | 1265 | 0.300 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.300 |
Why?
|
| Patient Selection | 5 | 2022 | 592 | 0.300 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2019 | 48 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2016 | 234 | 0.290 |
Why?
|
| Pressure | 3 | 2020 | 252 | 0.290 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2007 | 4 | 0.290 |
Why?
|
| Nasopharyngeal Diseases | 1 | 2007 | 2 | 0.290 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2007 | 31 | 0.290 |
Why?
|
| Efficiency | 3 | 2019 | 49 | 0.290 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2006 | 4 | 0.290 |
Why?
|
| Bone and Bones | 1 | 2007 | 145 | 0.280 |
Why?
|
| Congenital Abnormalities | 2 | 2006 | 42 | 0.280 |
Why?
|
| Spinal Puncture | 4 | 2011 | 38 | 0.280 |
Why?
|
| Papilloma, Inverted | 3 | 2004 | 8 | 0.270 |
Why?
|
| Cysts | 1 | 2007 | 70 | 0.270 |
Why?
|
| Hemangiopericytoma | 1 | 2006 | 5 | 0.270 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 176 | 0.270 |
Why?
|
| Bone Resorption | 1 | 2006 | 64 | 0.270 |
Why?
|
| Aspirin | 2 | 2020 | 295 | 0.270 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2007 | 105 | 0.270 |
Why?
|
| Prednisone | 2 | 2010 | 104 | 0.260 |
Why?
|
| Oxygen | 2 | 2007 | 386 | 0.260 |
Why?
|
| Facial Bones | 1 | 2005 | 10 | 0.260 |
Why?
|
| Cytoplasmic Granules | 1 | 2005 | 19 | 0.260 |
Why?
|
| Lasers | 1 | 2005 | 61 | 0.260 |
Why?
|
| Craniofacial Abnormalities | 1 | 2005 | 18 | 0.260 |
Why?
|
| Algorithms | 3 | 2016 | 1195 | 0.260 |
Why?
|
| Exophthalmos | 1 | 2005 | 6 | 0.260 |
Why?
|
| Hemangioma | 1 | 2006 | 51 | 0.260 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 1753 | 0.260 |
Why?
|
| Methacholine Chloride | 4 | 2012 | 20 | 0.260 |
Why?
|
| Dissection | 2 | 2018 | 29 | 0.250 |
Why?
|
| Disease Progression | 4 | 2016 | 1037 | 0.250 |
Why?
|
| Gene Expression Regulation | 4 | 2014 | 1293 | 0.240 |
Why?
|
| Radiography | 3 | 2015 | 572 | 0.240 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.240 |
Why?
|
| Hypertrophy | 2 | 2022 | 89 | 0.240 |
Why?
|
| Histamine Antagonists | 2 | 2021 | 22 | 0.240 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1040 | 0.240 |
Why?
|
| Animals | 13 | 2018 | 20880 | 0.230 |
Why?
|
| Exhalation | 2 | 2020 | 7 | 0.230 |
Why?
|
| Fluticasone | 2 | 2020 | 12 | 0.230 |
Why?
|
| Fibrin Tissue Adhesive | 2 | 2000 | 17 | 0.230 |
Why?
|
| Iron-Dextran Complex | 1 | 2023 | 3 | 0.220 |
Why?
|
| Patient Readmission | 2 | 2016 | 267 | 0.220 |
Why?
|
| Acoustics | 2 | 2020 | 20 | 0.220 |
Why?
|
| Sella Turcica | 3 | 2020 | 10 | 0.220 |
Why?
|
| Rhinomanometry | 1 | 2022 | 2 | 0.220 |
Why?
|
| South Carolina | 4 | 2020 | 2752 | 0.220 |
Why?
|
| Consensus | 3 | 2022 | 211 | 0.220 |
Why?
|
| Absenteeism | 4 | 2015 | 27 | 0.220 |
Why?
|
| Dermoid Cyst | 1 | 2002 | 4 | 0.210 |
Why?
|
| Frontal Lobe | 1 | 2004 | 156 | 0.210 |
Why?
|
| Body Mass Index | 4 | 2016 | 866 | 0.210 |
Why?
|
| Pleasure | 1 | 2022 | 5 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2013 | 56 | 0.210 |
Why?
|
| Quality of Health Care | 3 | 2017 | 322 | 0.210 |
Why?
|
| Fungemia | 1 | 2002 | 13 | 0.210 |
Why?
|
| Isoproterenol | 2 | 2012 | 163 | 0.210 |
Why?
|
| Fibroblasts | 3 | 2016 | 902 | 0.210 |
Why?
|
| Alberta | 3 | 2017 | 15 | 0.210 |
Why?
|
| Artifacts | 1 | 2003 | 125 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 710 | 0.210 |
Why?
|
| Adenoidectomy | 2 | 2012 | 51 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 848 | 0.200 |
Why?
|
| Elective Surgical Procedures | 2 | 2020 | 95 | 0.200 |
Why?
|
| Drug Approval | 1 | 2022 | 50 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2015 | 330 | 0.200 |
Why?
|
| Frailty | 1 | 2022 | 34 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 1 | 2003 | 153 | 0.200 |
Why?
|
| Mutation | 1 | 2007 | 1213 | 0.200 |
Why?
|
| Cryotherapy | 1 | 2021 | 36 | 0.190 |
Why?
|
| Infant, Newborn | 4 | 2020 | 2455 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2021 | 31 | 0.190 |
Why?
|
| Gray Matter | 1 | 2021 | 57 | 0.190 |
Why?
|
| Cost of Illness | 3 | 2022 | 204 | 0.190 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 27 | 0.190 |
Why?
|
| Viral Vaccines | 1 | 2020 | 17 | 0.190 |
Why?
|
| Viruses | 1 | 2020 | 14 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 25 | 0.180 |
Why?
|
| Injections, Subcutaneous | 2 | 2012 | 87 | 0.180 |
Why?
|
| Mastoid | 1 | 2020 | 20 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 196 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2003 | 601 | 0.180 |
Why?
|
| Pneumococcal Infections | 1 | 2000 | 30 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2020 | 40 | 0.180 |
Why?
|
| Central Nervous System Cysts | 1 | 2020 | 5 | 0.180 |
Why?
|
| Nitric Oxide | 4 | 2000 | 382 | 0.180 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.180 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1034 | 0.180 |
Why?
|
| Vibration | 1 | 2020 | 32 | 0.180 |
Why?
|
| Brain Abscess | 1 | 2019 | 7 | 0.180 |
Why?
|
| Receptors, Odorant | 1 | 2019 | 2 | 0.180 |
Why?
|
| Survival Rate | 3 | 2021 | 1055 | 0.170 |
Why?
|
| Biometry | 1 | 2020 | 72 | 0.170 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2019 | 20 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 51 | 0.170 |
Why?
|
| Patient Outcome Assessment | 2 | 2016 | 42 | 0.170 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2019 | 14 | 0.170 |
Why?
|
| Cell Count | 2 | 2011 | 248 | 0.170 |
Why?
|
| Space Flight | 1 | 2020 | 40 | 0.170 |
Why?
|
| Cerebrospinal Fluid Pressure | 2 | 2011 | 13 | 0.170 |
Why?
|
| Health Status | 2 | 2020 | 429 | 0.170 |
Why?
|
| Nerve Regeneration | 1 | 2019 | 42 | 0.170 |
Why?
|
| Goals | 1 | 2019 | 65 | 0.160 |
Why?
|
| Macrophages | 2 | 2014 | 647 | 0.160 |
Why?
|
| Phenylthiourea | 1 | 2018 | 2 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 1745 | 0.160 |
Why?
|
| Interleukin-5 | 2 | 2011 | 14 | 0.160 |
Why?
|
| Trigeminal Nerve | 1 | 2018 | 22 | 0.160 |
Why?
|
| Rhinosporidiosis | 1 | 2018 | 7 | 0.160 |
Why?
|
| Canada | 2 | 2016 | 266 | 0.160 |
Why?
|
| Olfactory Perception | 1 | 2018 | 20 | 0.160 |
Why?
|
| Drinking | 1 | 2018 | 35 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 8 | 0.160 |
Why?
|
| Brain | 2 | 2021 | 2176 | 0.160 |
Why?
|
| Decompression, Surgical | 2 | 2010 | 55 | 0.160 |
Why?
|
| Dysgeusia | 1 | 2018 | 4 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.160 |
Why?
|
| Reference Values | 3 | 2012 | 579 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 239 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2018 | 144 | 0.160 |
Why?
|
| Receptors, Complement | 1 | 2018 | 58 | 0.150 |
Why?
|
| Perforin | 1 | 2017 | 12 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 799 | 0.150 |
Why?
|
| Granzymes | 1 | 2017 | 19 | 0.150 |
Why?
|
| Research Design | 3 | 2020 | 729 | 0.150 |
Why?
|
| Eating | 1 | 2018 | 119 | 0.150 |
Why?
|
| Models, Economic | 2 | 2014 | 69 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 648 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 503 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2017 | 714 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 786 | 0.150 |
Why?
|
| Skin Tests | 2 | 2018 | 30 | 0.150 |
Why?
|
| Bone Density | 1 | 2018 | 159 | 0.150 |
Why?
|
| Neurogenic Inflammation | 1 | 2016 | 4 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2016 | 880 | 0.140 |
Why?
|
| Chordoma | 1 | 2016 | 9 | 0.140 |
Why?
|
| Economics | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sick Leave | 1 | 2016 | 6 | 0.140 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 100 | 0.140 |
Why?
|
| Monocytes | 1 | 2017 | 210 | 0.140 |
Why?
|
| Sensory Thresholds | 1 | 2016 | 50 | 0.140 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2006 | 12 | 0.140 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 36 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2016 | 119 | 0.130 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 8 | 0.130 |
Why?
|
| Phospholipids | 2 | 2006 | 108 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 597 | 0.130 |
Why?
|
| Recurrence | 2 | 2020 | 948 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2015 | 33 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2015 | 50 | 0.130 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 60 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 61 | 0.130 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 27 | 0.130 |
Why?
|
| Liposomes | 1 | 2015 | 107 | 0.130 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 25 | 0.130 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2014 | 14 | 0.130 |
Why?
|
| Cost Savings | 1 | 2015 | 110 | 0.120 |
Why?
|
| Visual Analog Scale | 1 | 2014 | 8 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 285 | 0.120 |
Why?
|
| Age Distribution | 2 | 2008 | 319 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2014 | 53 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 536 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2017 | 413 | 0.120 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2015 | 31 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 370 | 0.120 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 306 | 0.120 |
Why?
|
| Cell Movement | 1 | 2017 | 630 | 0.120 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Interleukins | 1 | 2014 | 79 | 0.120 |
Why?
|
| Decision Making | 2 | 2014 | 410 | 0.120 |
Why?
|
| Diuretics | 1 | 2014 | 96 | 0.120 |
Why?
|
| Cell Line | 3 | 2018 | 1752 | 0.120 |
Why?
|
| Tertiary Healthcare | 1 | 2014 | 6 | 0.120 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 23 | 0.120 |
Why?
|
| Nervous System Malformations | 1 | 2014 | 7 | 0.120 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 56 | 0.120 |
Why?
|
| Calcifediol | 1 | 2014 | 70 | 0.120 |
Why?
|
| Vitamins | 1 | 2015 | 134 | 0.120 |
Why?
|
| Abducens Nerve Diseases | 1 | 2013 | 5 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 41 | 0.120 |
Why?
|
| International Cooperation | 1 | 2014 | 88 | 0.120 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 977 | 0.110 |
Why?
|
| Biofilms | 1 | 2014 | 72 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 85 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 381 | 0.110 |
Why?
|
| Equipment and Supplies | 1 | 2013 | 18 | 0.110 |
Why?
|
| Forced Expiratory Volume | 1 | 2013 | 87 | 0.110 |
Why?
|
| Presenteeism | 3 | 2019 | 7 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 689 | 0.110 |
Why?
|
| Immunity, Innate | 2 | 2019 | 156 | 0.110 |
Why?
|
| Pain | 1 | 2016 | 472 | 0.110 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 16 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2012 | 765 | 0.110 |
Why?
|
| Postoperative Care | 2 | 2011 | 163 | 0.110 |
Why?
|
| Otitis Media with Effusion | 1 | 2012 | 9 | 0.110 |
Why?
|
| Cyclopropanes | 1 | 2012 | 10 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 2012 | 19 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1663 | 0.110 |
Why?
|
| Memory Disorders | 2 | 2019 | 111 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 301 | 0.110 |
Why?
|
| Pain Measurement | 1 | 2013 | 328 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 371 | 0.110 |
Why?
|
| Postoperative Period | 2 | 2022 | 238 | 0.110 |
Why?
|
| Physical Stimulation | 1 | 2012 | 67 | 0.110 |
Why?
|
| Sulfides | 1 | 2012 | 43 | 0.100 |
Why?
|
| Quinolines | 1 | 2012 | 48 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2012 | 216 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 9 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 929 | 0.100 |
Why?
|
| Polyneuropathies | 1 | 2012 | 6 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2012 | 21 | 0.100 |
Why?
|
| Acetates | 1 | 2012 | 74 | 0.100 |
Why?
|
| Ventilator Weaning | 1 | 2012 | 27 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 39 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 58 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.100 |
Why?
|
| Phenol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Muscular Diseases | 1 | 2012 | 41 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2550 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 503 | 0.100 |
Why?
|
| Oropharynx | 1 | 2011 | 20 | 0.100 |
Why?
|
| Standard of Care | 1 | 2011 | 22 | 0.100 |
Why?
|
| Glycerol | 1 | 2011 | 26 | 0.100 |
Why?
|
| B7-2 Antigen | 1 | 2011 | 23 | 0.100 |
Why?
|
| Osteoma | 2 | 2009 | 6 | 0.100 |
Why?
|
| B7-1 Antigen | 1 | 2011 | 20 | 0.100 |
Why?
|
| Sampling Studies | 1 | 2011 | 80 | 0.100 |
Why?
|
| Accessory Nerve | 1 | 2011 | 1 | 0.100 |
Why?
|
| Th1-Th2 Balance | 1 | 2011 | 10 | 0.100 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 378 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.100 |
Why?
|
| Blood Circulation | 1 | 2011 | 18 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 329 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2011 | 45 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 507 | 0.090 |
Why?
|
| Cellulase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 83 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 119 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1738 | 0.090 |
Why?
|
| Electrophoresis | 1 | 2011 | 69 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2011 | 241 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2009 | 10 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 85 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2010 | 77 | 0.090 |
Why?
|
| Models, Biological | 2 | 2011 | 981 | 0.090 |
Why?
|
| Intraoperative Care | 1 | 2010 | 91 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 93 | 0.090 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 16 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 148 | 0.090 |
Why?
|
| Rabbits | 2 | 2000 | 509 | 0.090 |
Why?
|
| Surface-Active Agents | 1 | 2010 | 57 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2012 | 142 | 0.090 |
Why?
|
| Nasal Provocation Tests | 1 | 2009 | 2 | 0.090 |
Why?
|
| Superantigens | 1 | 2009 | 7 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 201 | 0.090 |
Why?
|
| Angiofibroma | 1 | 2009 | 4 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2009 | 98 | 0.080 |
Why?
|
| Tampons, Surgical | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cautery | 1 | 2009 | 5 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 237 | 0.080 |
Why?
|
| Immunization | 1 | 2009 | 86 | 0.080 |
Why?
|
| Conjunctivitis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 424 | 0.080 |
Why?
|
| Skull Neoplasms | 1 | 2009 | 23 | 0.080 |
Why?
|
| Education, Professional | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cartilage | 2 | 1999 | 51 | 0.080 |
Why?
|
| Proteome | 2 | 2020 | 87 | 0.080 |
Why?
|
| Complement Activation | 1 | 2010 | 145 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2011 | 682 | 0.080 |
Why?
|
| Chemokine CCL11 | 2 | 2007 | 9 | 0.080 |
Why?
|
| Photomicrography | 1 | 2008 | 14 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 206 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 86 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.080 |
Why?
|
| Education | 1 | 2009 | 83 | 0.080 |
Why?
|
| Diet | 3 | 2021 | 514 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 951 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 49 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 100 | 0.080 |
Why?
|
| Debridement | 2 | 2010 | 55 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 785 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2008 | 249 | 0.080 |
Why?
|
| Morbidity | 1 | 2008 | 130 | 0.070 |
Why?
|
| Fungal Proteins | 1 | 2007 | 37 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2018 | 2689 | 0.070 |
Why?
|
| Self Care | 1 | 2009 | 252 | 0.070 |
Why?
|
| Glasgow Outcome Scale | 1 | 2007 | 15 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2007 | 251 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 254 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 150 | 0.070 |
Why?
|
| Brain Edema | 1 | 2007 | 50 | 0.070 |
Why?
|
| Mice | 4 | 2018 | 8474 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2007 | 42 | 0.070 |
Why?
|
| Memory, Short-Term | 1 | 2007 | 79 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 938 | 0.070 |
Why?
|
| Patient Participation | 2 | 2019 | 145 | 0.070 |
Why?
|
| Cerebellum | 1 | 2007 | 103 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 492 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 50 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 349 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 258 | 0.070 |
Why?
|
| Mucins | 1 | 2005 | 22 | 0.070 |
Why?
|
| Physical Examination | 2 | 2018 | 152 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2020 | 411 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 100 | 0.060 |
Why?
|
| Complementary Therapies | 2 | 2018 | 43 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 127 | 0.060 |
Why?
|
| Autoanalysis | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 296 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 32 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2005 | 58 | 0.060 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2004 | 4 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2004 | 18 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunoassay | 1 | 2004 | 64 | 0.060 |
Why?
|
| Smoking | 2 | 2010 | 1449 | 0.060 |
Why?
|
| Decision Trees | 2 | 2014 | 74 | 0.060 |
Why?
|
| Sarcoma | 1 | 2005 | 70 | 0.060 |
Why?
|
| Complement C3 | 2 | 2018 | 101 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2006 | 954 | 0.060 |
Why?
|
| Anti-Infective Agents | 2 | 2010 | 166 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 193 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 124 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 415 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2008 | 657 | 0.060 |
Why?
|
| Pneumoencephalography | 1 | 2003 | 3 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 215 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 219 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2003 | 112 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2022 | 35 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 244 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 219 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2003 | 42 | 0.050 |
Why?
|
| Heart Conduction System | 1 | 2003 | 119 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 31 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 81 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 517 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 131 | 0.050 |
Why?
|
| Drainage | 1 | 2002 | 133 | 0.050 |
Why?
|
| Protective Clothing | 1 | 2021 | 12 | 0.050 |
Why?
|
| Melanoma | 1 | 2005 | 335 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 151 | 0.050 |
Why?
|
| Clindamycin | 1 | 2000 | 25 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 204 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 30 | 0.050 |
Why?
|
| Hyperemia | 1 | 2020 | 14 | 0.050 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 1 | 0.050 |
Why?
|
| Lung | 1 | 2005 | 849 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2000 | 236 | 0.050 |
Why?
|
| Staphylococcus | 1 | 2020 | 29 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 39 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2020 | 106 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 109 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 124 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 40 | 0.040 |
Why?
|
| Bone Substitutes | 1 | 1999 | 20 | 0.040 |
Why?
|
| Tissue Adhesives | 1 | 1999 | 17 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 52 | 0.040 |
Why?
|
| Thinking | 1 | 2019 | 30 | 0.040 |
Why?
|
| Historically Controlled Study | 1 | 2019 | 7 | 0.040 |
Why?
|
| Acetazolamide | 1 | 2019 | 8 | 0.040 |
Why?
|
| Second Messenger Systems | 2 | 1997 | 53 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 791 | 0.040 |
Why?
|
| Suture Techniques | 1 | 1999 | 75 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Workplace | 1 | 2019 | 75 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 159 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Psychometrics | 1 | 2021 | 514 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 242 | 0.040 |
Why?
|
| Hearing Tests | 1 | 2018 | 70 | 0.040 |
Why?
|
| Probiotics | 1 | 2018 | 14 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2012 | 652 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 83 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2017 | 35 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2018 | 68 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 201 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 116 | 0.040 |
Why?
|
| Parasympathomimetics | 1 | 1997 | 13 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 349 | 0.040 |
Why?
|
| Internationality | 1 | 2017 | 74 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 94 | 0.040 |
Why?
|
| Muscarinic Agonists | 1 | 1997 | 17 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 532 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2017 | 228 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 706 | 0.040 |
Why?
|
| Neutrophils | 1 | 2017 | 204 | 0.030 |
Why?
|
| Regional Health Planning | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 104 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 177 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 62 | 0.030 |
Why?
|
| North America | 1 | 2016 | 111 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 369 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 199 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1995 | 11 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 28 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Substance P | 1 | 1995 | 39 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 1995 | 27 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2015 | 50 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.030 |
Why?
|
| Neck | 1 | 2015 | 62 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2018 | 269 | 0.030 |
Why?
|
| Bibliometrics | 1 | 2015 | 25 | 0.030 |
Why?
|
| Patients | 1 | 2015 | 69 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 114 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 235 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 331 | 0.030 |
Why?
|
| Neoplasms | 1 | 2006 | 1664 | 0.030 |
Why?
|
| Insurance, Surgical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 247 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2015 | 52 | 0.030 |
Why?
|
| Motivation | 1 | 2019 | 561 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 341 | 0.030 |
Why?
|
| Oregon | 1 | 2014 | 7 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 403 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.030 |
Why?
|
| California | 1 | 2014 | 99 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 105 | 0.030 |
Why?
|
| Drug Costs | 1 | 2014 | 87 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 133 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 166 | 0.030 |
Why?
|
| Tissue Adhesions | 1 | 2013 | 21 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2013 | 19 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2013 | 25 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 230 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 2013 | 9 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2011 | 275 | 0.030 |
Why?
|
| Heart Block | 1 | 1972 | 49 | 0.030 |
Why?
|
| Safety | 1 | 2013 | 145 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 123 | 0.030 |
Why?
|
| Otitis Media | 1 | 2012 | 35 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2012 | 67 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 164 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 158 | 0.030 |
Why?
|
| Endoscopes | 1 | 2012 | 36 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 489 | 0.030 |
Why?
|
| Germany | 1 | 2012 | 67 | 0.030 |
Why?
|
| Physicians | 1 | 2015 | 324 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 114 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 260 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 196 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 1972 | 157 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1174 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 261 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 595 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 149 | 0.020 |
Why?
|
| Hoarseness | 1 | 2010 | 6 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1972 | 239 | 0.020 |
Why?
|
| Complement Factor B | 1 | 2010 | 19 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 423 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2010 | 34 | 0.020 |
Why?
|
| Solutions | 1 | 2010 | 115 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1046 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 189 | 0.020 |
Why?
|
| Autopsy | 1 | 2009 | 56 | 0.020 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2008 | 32 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2008 | 62 | 0.020 |
Why?
|
| Computer Systems | 1 | 2008 | 42 | 0.020 |
Why?
|
| Immune System | 1 | 2007 | 63 | 0.020 |
Why?
|
| Cerebellar Diseases | 1 | 2007 | 6 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2007 | 65 | 0.020 |
Why?
|
| Optic Nerve | 1 | 2007 | 55 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2007 | 54 | 0.020 |
Why?
|
| Cyclic GMP | 2 | 1997 | 99 | 0.020 |
Why?
|
| Atropine | 2 | 1997 | 29 | 0.020 |
Why?
|
| Neurilemmoma | 1 | 2006 | 26 | 0.020 |
Why?
|
| Prostaglandins | 2 | 1997 | 65 | 0.020 |
Why?
|
| Cyclic AMP | 2 | 1997 | 223 | 0.020 |
Why?
|
| Muscarinic Antagonists | 2 | 1997 | 54 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1996 | 72 | 0.020 |
Why?
|
| Nerve Net | 1 | 2007 | 180 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 626 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 129 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 125 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2007 | 531 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 2791 | 0.010 |
Why?
|
| Fibroma, Ossifying | 1 | 2002 | 5 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 338 | 0.010 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2002 | 6 | 0.010 |
Why?
|
| Densitometry | 1 | 1999 | 15 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 219 | 0.010 |
Why?
|
| Random Allocation | 1 | 1999 | 442 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1997 | 64 | 0.010 |
Why?
|
| Terbutaline | 1 | 1996 | 23 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 92 | 0.010 |
Why?
|
| Epithelium | 1 | 1996 | 172 | 0.010 |
Why?
|
| Diclofenac | 1 | 1995 | 11 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 2083 | 0.010 |
Why?
|
| Adams-Stokes Syndrome | 1 | 1972 | 2 | 0.010 |
Why?
|
| Atrial Flutter | 1 | 1972 | 16 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 156 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1972 | 53 | 0.010 |
Why?
|
| Bradycardia | 1 | 1972 | 45 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 5300 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 1972 | 248 | 0.010 |
Why?
|